Ng J

No ORCID on file · 10 papers in corpus · active 2017-2025

Study types

  • article 5
  • rct 2

Condition tags

  • endometriosis 6
  • dysmenorrhea 3
  • chronic_pelvic_pain 3
  • dyspareunia 2
2025
Disrupted glucocorticoid receptor cell signalling causes a ciliogenesis defect in the fetal mouse renal tubule.
EMBO reports ·doi:10.1038/s44319-025-00454-0

Primary cilia are cell signalling and environment sensing organelles and have important roles during embryogenesis and homeostasis. We demonstrate glucocorticoid signalling is essential for normal cilia formation in mouse and human renal tu…

rct 2024
Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial
American journal of obstetrics and gynecology ·doi:10.1016/j.ajog.2024.06.040

BACKGROUND: Elagolix, an approved oral treatment for endometriosis-associated pain, has been associated with hypoestrogenic effects when used as monotherapy. Hormonal add-back therapy has the potential to mitigate these effects. OBJECTIVE:…

2023
Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome.
F&S reports ·doi:10.1016/j.xfre.2023.02.007

ObjectiveEvaluate the efficacy and safety of elagolix, a GnRH antagonist, to treat polycystic ovarian syndrome (PCOS).DesignA phase 2, multicenter, double-blind, randomized, placebo-controlled trial.SettingOutpatient and academic medical ce…

2022
Preventing Surgery-Induced NK Cell Dysfunction Using Anti-TGF-β Immunotherapeutics.
International journal of molecular sciences ·doi:10.3390/ijms232314608

Natural Killer (NK) cell cytotoxicity and interferon-gamma (IFNγ) production are profoundly suppressed postoperatively. This dysfunction is associated with increased morbidity and cancer recurrence. NK activity depends on the integration of…

article 2021
Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis
Clinical and translational science ·doi:10.1111/cts.13040

Abstract Elagolix is a novel, oral gonadotropin‐releasing hormone receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids. Consi…

article 2020
Exposure‐Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis‐Associated Pain
CPT: pharmacometrics & systems pharmacology ·doi:10.1002/psp4.12560

Elagolix is a novel oral gonadotropin releasing hormone receptor antagonist, that can suppress estradiol in a dose‐dependent manner. It is indicated for management of moderate‐to‐severe pain associated with endometriosis. A population expos…

article 2018
Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment
Clinical pharmacology in drug development ·doi:10.1002/cpdd.640

The aim of these studies was to assess the safety and pharmacokinetics of elagolix, an oral nonpeptide gonadotropin-releasing hormone antagonist following oral administration in women with renal or hepatic impairment. Two phase 1 studies we…

article 2018
Long-Term Outcomes of Elagolix in Women With Endometriosis
Obstetrics and gynecology ·doi:10.1097/aog.0000000000002675

OBJECTIVE: To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain. METHODS: Elaris Endometriosis (EM)-III and -IV were exten…

article 2018
Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis
Clinical pharmacokinetics ·doi:10.1007/s40262-018-0629-6

IntroductionElagolix is a novel, orally active, non-peptide, competitive gonadotropin-releasing hormone (GnRH) receptor antagonist in development for the management of endometriosis with associated pain and heavy menstrual bleeding due to u…

rct 2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
The New England journal of medicine ·doi:10.1056/NEJMoa1700089

BACKGROUND: Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppres…